Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brigatinib after progression on alectinib or ceritinib in ALK-positive advanced non-small-cell lung cancer
jRCT2080224831Phase 2Completed
- Sponsor
- Takeda
- Start
- Aug 2019
- Modality
- Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of brigatinib in non-small cell lung cancer (NSCLC), sponsored by Takeda. Started Aug 2019; status: completed.
02
Drugs
brigatinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCT2080224831.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224831.